BRAF mutant colorectal cancer is a heterogeneous tumor subtype with variable efficacy for immune checkpoint blockade therapy, and the exploration of new predictive biomarkers for screening immunotherapy-sensitive populations other than MSI-H should continue to be encouraged. Here, BRAF is linked to neoplasm.